Managing side effects of angiogenesis inhibitors in renal cell carcinoma

Area of Science:

• Oncology
• Pharmacology

Background:

• Metastatic renal cell carcinoma (RCC) predominantly treated with anti-angiogenetic agents.
• Targeted therapies, such as tyrosine kinase inhibitors, offer a new approach to RCC treatment.
• These targeted therapies are perceived as less toxic than traditional chemotherapy or immunotherapy.

Purpose of the Study:

• To review the significance of adverse events in patients undergoing targeted therapy for RCC.
• To provide guidance for clinical oncologists on patient surveillance and management of treatment-related side effects.
• To tailor surveillance strategies for specific side effects of individual targeted agents.

Main Methods:

• Review of current literature on adverse events associated with targeted therapies in RCC.
• Analysis of the mechanisms of action and targets of tyrosine kinase inhibitors in RCC.
• Synthesis of information on side effect management protocols.

Main Results:

• Targeted therapies, while effective, present unique side effect profiles.
• Understanding drug targets in tumors and patients is crucial for managing toxicity.
• Development of specific surveillance and management strategies is necessary.

Conclusions:

• Adverse event management is critical for optimizing targeted therapy in RCC.
• Oncologists require updated guidance to navigate the complexities of targeted therapy side effects.
• Personalized patient care involves tailored surveillance and treatment of adverse events.